| Authors: |
Zweifel M; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood., Jayson GC; School of Cancer and Enabling Sciences, University of Manchester & Christie Hospital, Manchester., Reed NS; Beatson Oncology Centre, Western Infirmary, Glasgow., Osborne R; Dorset Cancer Centre, Poole Hospital NHS Foundation Trust, Poole., Hassan B; Department of Medical Oncology, Churchill Hospital, Oxford., Ledermann J; UCL Cancer Institute, Cancer Research UK & University College of London Cancer Trials Centre, London, UK., Shreeves G; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood., Poupard L; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood., Lu SP; OXiGENE Inc., San Francisco, USA., Balkissoon J; OXiGENE Inc., San Francisco, USA., Chaplin DJ; OXiGENE Inc., San Francisco, USA., Rustin GJS; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood. Electronic address: grustin@nhs.net. |
